natgillin/translations-raw huggingface dataset:
Balanitis or balanoposthitis occurred primarily in uncircumcised male patients. 
Do balanitisa oziroma balanopostitisa je prihajalo predvsem pri moških bolnikih, ki niso bili obrezani.
In in vitro studies, canagliflozin neither inhibited cytochrome P450 CYP1A2,CYP2A6, CYP2C19, CYP2D6, or CYP2E1, CYP2B6, CYP2C8, CYP2C9, nor induced CYP1A2, CYP2C19, CYP2B6, CYP3A4 at higher than therapeutic concentrations. 
V in vitro študijah kanagliflozin pri odmerkih, višjih od terapevtskih, ni niti zaviral izoencimov citokroma P450 CYP1A2,CYP2A6, CYP2C19, CYP2D6, ali CYP2E1, CYP2B6, CYP2C8, CYP2C9, niti induciral CYP1A2, CYP2C19, CYP2B6, CYP3A4.
Male and female patients with a history of genital mycotic infections were more likely to develop an infection. 
Pri bolnikih moškega in ženskega spola, ki so imeli genitalno glivično okužbo v anamnezi, je bila verjetnost za razvoj okužbe večja.
INFORMATION IN BRAILLE invokana 100 mg invokana 300 mg 
PODATKI V BRAILLOVI PISAVI invokana 100 mg invokana 300 mg
Patients should be advised to report symptoms of volume depletion. 
Bolnikom je treba naročiti, naj zdravniku povedo za simptome hipovolemije.
If you take more of this medicine than you should, talk to a doctor straight away. 
Če ste vzeli večji odmerek zdravila Invokana, kot bi smeli Če vzamete več zdravila, kot bi smeli, takoj obvestite zdravnika.
This happens more often in elderly people (aged 75 and over), people with kidney problems, and people taking water tablets (diuretics). 
Pogosteje se pojavi pri starejših ljudeh (starih 75 let ali več), pri ljudeh z boleznijo ledvic in pri ljudeh, ki jemljejo zdravila za odvajanje vode (diuretike).
These symptoms could be a sign of “diabetic ketoacidosis” - a problem you can get with diabetes because of increased levels of “ketone bodies” in your urine or blood, seen in tests. 
Ti simptomi so lahko znaki “diabetične ketoacidoze” - motnje, ki se lahko pojavi pri sladkorni bolezni zaradi povečane koncentracije “ketonskih teles” v urinu in krvi, kar pokažejo laboratorijske preiskave.
The Leydig cell tumours are associated with an increase in luteinizing hormone (LH), which is a known mechanism of Leydig cell tumour formation in rats. 
Tumorji Leydigovih celic so povezani zvišanjem koncentracije luteinizirajočega hormona (LH), kar je že znan mehanizem tvorbe tumorja Leydigovih celic pri podganah.
Experience in New York Heart Association (NYHA) class III is limited, and there is no experience in clinical studies with canagliflozin in NYHA class IV. 
Pri bolnikih razreda III po Newyorškem združenju za srce (NYHA - New York Heart Association) je izkušenj malo, pri bolnikih razreda NYHA IV v okviru kliničnih študij ni nobenih izkušenj z uporabo kanagliflozina.
Invokana is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as: 
Zdravilo Invokana je indicirano pri odraslih, starih 18 let ali več, ki imajo sladkorno bolezen tipa 2, za izboljšanje urejenosti glikemije kot:
Monitoring of renal function is recommended as follows: - Prior to initiation of canagliflozin and at least annually, thereafter (see sections 4.2, 4.8, 5.1, and 
Priporočeno je spremljanje delovanja ledvic, in sicer: - pred uvedbo kanagliflozina, nato pa najmanj enkrat na leto (glejte poglavja 4.2, 4.8, 5.1 in 5.2)
Inhibition of BCRP by canagliflozin cannot be excluded at an intestinal level and increased exposure may therefore occur for medicinal products transported by BCRP, e.g. certain statins like rosuvastatin and some anti-cancer medicinal products. 
Zaviranja BCRP v črevesju s kanagliflozinom ni mogoče izključiti, zato lahko pride do povečane izpostavljenosti zdravilom, ki jih prenaša BCRP (npr. nekateri statini, kot je rosuvastatin in nekatere učinkovine za zdravljenje rakavih bolezni).
Available pharmacodynamic/toxicological data in animals have shown excretion of canagliflozin/metabolites in milk, as well as pharmacologically mediated effects in breast-feeding offspring and juvenile rats exposed to canagliflozin (see section 5.3). 
Razpoložljivi farmakološki/toksikološki podatki pri živalih kažejo, da se kanagliflozin oz. njegovi presnovki izločajo v mleko, kot tudi farmakološke učinke na dojene mladiče in mlade podgane, ki so bile izpostavljene kanagliflozinu (glejte poglavje 5.3).
Table 3: Efficacy results from active-controlled clinical studiesa 
Preglednica 3: Rezultati učinkovitosti iz aktivno nadzorovanih kliničnih študija
In a number of cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14 mmol/l (250 mg/dl). 
Potek bolezni je bil v številnih primerih atipičen, z le zmerno zvečano koncentracijo glukoze v krvi, pod 14 mmol/l (250 mg/dl).
• If you forget to take a dose, take it as soon as you remember. 
Če ste pozabili vzeti zdravilo Invokana • Če ste pozabili vzeti odmerek, ga vzemite takoj, ko se spomnite.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s svojim zdravnikom
• The other ingredients are: tablet core: croscarmellose sodium, hydroxypropyl cellulose, lactose anhydrous, magnesium stearate, and microcrystalline cellulose film-coating: macrogol (3350), polyvinyl alcohol, talc, and titanium dioxide (E171). 
• Druge sestavine zdravila so: jedro tablete: premrežen natrijev karmelozat, hidroksipropil celuloza, brezvodna laktoza, magnezijev stearat in mikrokristalna celuloza; filmska obloga: makrogol (3350), polivinil alkohol, smukec in titanov dioksid (E171).
In a pooled analysis of eight placebo-controlled and active-controlled studies, the safety profile in elderly patients was generally consistent with younger patients. 
V združeni analizi podatkov iz osmih s placebom in z učinkovino nadzorovanih študij, je bil varnostni profil zdravila pri starejših bolnikih večinoma enak kot pri mlajših bolnikih.
Placebo-controlled studies 
S placebom nadzorovane študije
No effects on fertility were observed in animal studies (see section 5.3). 
V študijah na živalih niso opazili vpliva na plodnost (glejte poglavje 5.3).
It is also important to keep following advice about diet and exercise given by your doctor or nurse. 
Pri zdravljenju je pomembno, da upoštevate tudi navodila glede diete in telesne dejavnosti, ki sta vam jih dala zdravnik ali medicinska sestra.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in na škatli poleg oznake "Uporabno do".
Canagliflozin should not be used during pregnancy. 
Kanagliflozin se ne sme uporabljati med nosečnostjo.
• efavirenz or ritonavir (a medicine used to treat HIV infection) 
• efavirenz ali ritonavir (zdravili, ki ju uporabljamo pri okužbi z virusom HIV)
CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans. 
Obseg z encimom CYP3A4 posredovanega (oksidativnega) metabolizma kanagliflozina pri ljudeh je majhen (znaša približno 7%).
There were no meaningful changes in bone density in trabecular and cortical regions. 
Pomembnih sprememb kostne gostote v trabekularni in kortikalni kostnini ni bilo.
In patients where DKA is suspected or diagnosed, treatment with canagliflozin should be discontinued immediately. 
Pri bolnikih, pri katerih obstaja sum na DKA ali že imajo diagnozo DKA, je treba zdravljenje s kanagliflozinom takoj prekiniti.
The effect of canagliflozin on fertility in humans has not been studied. 
Vpliva kanagliflozina na plodnost pri ljudeh niso preučevali.
Polyvinyl alcohol Titanium dioxide (E171) Macrogol 3350 
Filmska obloga polivinilalkohol titanov dioksid (E171) makrogol 335 smukec
5.3 Pre-clinical safety data 
5.3 Predklinični podatki o varnosti
Before initiating canagliflozin, factors in the patient history that may predispose to ketoacidosis should be considered. 
Pred uvedbo zdravljenja s kanagliflozinom je treba v bolnikovi anamnezi oceniti dejavnike, ki bi lahko povečali nagnjenost h ketoacidozi.
Patients with diabetes have been shown to have elevated renal glucose reabsorption which may contribute to persistent elevated blood glucose concentrations. 
Pokazalo se je, da je pri bolnikih s sladkorno boleznijo obseg reabsorbcije glukoze v ledvicah povečan, kar lahko prispeva k vztrajno zvišani koncentraciji glukoze v krvi.
Approximately 33% of the administered radioactive dose was excreted in urine, mainly as O-glucuronide metabolites (30.5%). 
Približno 33% danega radioaktivno označenega odmerka se je izločilo z urinom, največ v obliki O-glukuronidnih presnovkov (30,5%).
This can lead to serious medical conditions such as heart disease, kidney disease, blindness, and amputation. 
To lahko povzroča resna zdravstvena stanja, kot so bolezni srca in ledvic, slepota in amputacija (odstranitev katerega od udov ali njegovega dela).
The tablets contain lactose. 
Tablete vsebujejo laktozo.
• medicines used to lower your blood pressure (anti-hypertensives), including diuretics (medicines used to remove levels of excess water in the body, also known as water tablets) since this medicine can also lower your blood pressure by removing levels of excess water in the body. 
• zdravila za zniževanje krvnega tlaka (antihipertenzivi), vključno z diuretiki (zdravila za izločanje prevelike količine vode iz telesa), ker tudi to zdravilo lahko zniža vaš krvni tlak tako,
Overall, 0.7% of all female patients discontinued canagliflozin due to vulvovaginal candidiasis (see section 4.4). 
Skupno je 0,7% vseh bolnic prekinilo zdravljenje s kanagliflozinom zaradi vulvovaginalne kandidoze (glejte poglavje 4.4).
Maternal toxicity was limited to decreased body weight gain. 
Pri samicah je bila toksičnost omejena na zmanjšano telesno maso.
• low blood sugar levels (hypoglycaemia) - when taking this medicine with insulin or a sulphonylurea (such as glimepiride or glipizide). 
• nizka koncentracija sladkorja v krvi (hipoglikemija) - pri jemanju tega zdravila skupaj z insulinom ali sulfonilsečnino (na primer z glimepiridom ali glipizidom).
If a combined inducer of these UGT enzymes and transport proteins must be co-administered with canagliflozin, monitoring of glycaemic control to assess response to canagliflozin is appropriate. 
Če je sočasna uporaba induktorjev encimov UGT in transportnih proteinov s kangliflozinom neizogibna, je za presojo odziva na kanagliflozin smiselno spremljati urejenost glikemije.
When diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. 
Kadar samo dieta in telesna dejavnost ne zagotavljata zadostne urejenosti glikemije pri bolnikih, pri katerih uporaba metformina ni primerna zaradi neprenašanja ali kontraindikacij;
Studies characterising the pharmacokinetics of canagliflozin in paediatric patients have not been conducted. 
Pediatrična populacija Študij za ugotavljanje farmakokinetičnih lastnosti kanagliflozina pri pediatričnih bolnikih niso izvedli.
A pre-specified interim meta-analysis was conducted of adjudicated major cardiovascular events in the phase 2 and 3 clinical studies in 9,632 patients with type 2 diabetes, including 4,327 patients (44.9%) with cardiovascular disease or at high risk for cardiovascular disease who are participating in an ongoing cardiovascular study. 
Vnaprej dogovorjeno vmesno metaanalizo domnevnih večjih kardiovaskularnih dogodkov so izvedli na podatkih 9.632 bolnikov s sladkorno boleznijo tipa 2 iz kliničnih študij faze III in III, med katerimi je tudi 4.327 bolnikov (44,9%), ki imajo katero od kardiovaskularnih bolezni ali pa povečano tveganje za kardiovaskularne bolezni in so vključeni v kardiovaskularno študijo, ki še poteka.
Most infections were mild to moderate with no increase in the occurrence of serious adverse reactions. 
Večina okužb je bila blago do zmerno izražena, pogostnost resnih neželenih dogodkov pri tem ni bila povečana.
• if you have diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss, nausea, or vomiting). 
• če imate diabetično ketoacidozo (zaplet sladkorne bolezni z visoko koncentracijo sladkorja v krvi, s hitro izgubo telesne mase, z občutkom slabosti ali z bruhanjem.
Remember to take all medicines as directed by your doctor to achieve the best results for your health. 
Za najboljše rezultate zdravljenja jemljite vsa zdravila v skladu z navodili, ki vam jih da vaš zdravnik.
Canagliflozin is an orally-active inhibitor of SGLT2. 
Kanagliflozin je peroralno aktiven zaviralec prenašalca SGLT2.
This will help you remember to take it. 
Tako se boste lažje spomnili, da morate vzeti zdravilo.
• if you have severe kidney problems or are on dialysis 
• če imate hude težave z ledvicami ali se zdravite z dializo
Persistent renal findings in juvenile rats can most likely be attributed to reduced ability of the developing rat kidney to handle canagliflozin-increased urine volumes, as functional maturation of the rat kidney continues through 6 weeks of age. 
Opažene spremembe na ledvicah podganjih mladičev lahko najverjetneje pripišemo zmanjšani sposobnosti razvijajočih se ledvic podgan, da izločijo s kanagliflozinom povzročene povečane količine urina, saj funkcionalni razvoj podganjih ledvic poteka še v 6. tednu starosti.
Adverse reactions leading to discontinuation of ≥ 0.5% of all canagliflozin-treated patients in these studies were vulvovaginal candidiasis (0.7% of female patients) and balanitis or balanoposthitis (0.5% of male patients). 
Neželeni učinki, zaradi katerih so prekinili zdravljenje pri ≥ 0,5% vseh bolnikov, ki so v študijah prejemali kanagliflozin, so bili vulvovaginalna kandidoza (0,7% bolnic) in balanitis oziroma balanopostitis (0,5% bolnikov moškega spola).
The highest dose of 100 mg/kg provided up to 14 times the clinical dose of 300 mg based on AUC exposure. 
Najvišji odmerek 100 mg/kg predstavlja do 14-kratnik kliničnega odmerka 300 mg glede na izpostavljenost zdravilu (AUC).
Patients who may be at higher risk of DKA include patients with a low beta-cell function reserve (e.g., type 2 diabetes patients with low C-peptide or latent autoimmune diabetes in adults (LADA) or patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery or alcohol abuse. 
Bolniki z večjim tveganjem za DKA so lahko bolniki z majhno funkcijsko rezervo celic beta (bolniki s sladkorno boleznijo tipa 2 z majhno koncentracijo C-peptida ali latentno avtoimuno sladkorno boleznijo pri odraslih (LADA - latent autoimmune diabetes in adults) ali bolniki s pankreatitisom v anamnezi), bolniki s stanji, ki vodijo v omejen vnos hrane ali hudo dehidracijo, bolniki po zmanjšanju odmerka insulina in bolniki s povečanimi potrebami po insulinu zaradi akutnih bolezni, kirurških posegov ali zlorabe alkohola.
It is unknown whether ossification delays can be attributed to effects of canagliflozin on calcium homeostasis observed in adult rats. 
Ali lahko zakasnitve osifikacije pripišemo vplivu kanagliflozina na homeostazo kalcija, ki so ga opazili pri odraslih podganah, ni znano.
These decreases in exposure to canagliflozin may decrease efficacy. 
Tako zmanjšanje izpostavljenosti kanagliflozinu lahko zmanjša njegovo učinkovitost.
Due to its mechanism of action, canagliflozin, by increasing urinary glucose excretion (UGE) induces an osmotic diuresis, which may reduce intravascular volume and decrease blood pressure (see section 5.1). 
Kanagliflozin zaradi svojega mehanizma delovanja povečuje izločanje glukoze z urinom in tako povzroča osmotsko diurezo, ki lahko zmanjša znotrajžilni volumen in zniža krvni tlak (glejte poglavje 5.1).
• if you are allergic to canagliflozin or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Invokana - če ste alergični na kanagliflozin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Urinary uric acid excretion was transiently increased by canagliflozin (increased by 19% compared to baseline on day 1 and then attenuating to 6% on day 2 and 1% on day 13). 
Kanagliflozin je prehodno povečal izločanje sečne kisline z urinom (1. dan za 19% v primerjavi z izhodiščno vrednostjo, nato pa se je to povečanje postopoma zmanjševalo na 6% 2. dne in na 1% 13. dne).
• dabigatran (blood thinner medicine that lowers the risk of blood clot formation). 
• dabigatran (zdravilo za redčenje krvi, ki zmanjšuje nastajanje krvnih strdkov).
Restarting SGLT2 inhibitor treatment in patients with previous DKA while on SGLT2 inhibitor treatment is not recommended unless another clear precipitating factor is identified and resolved. 
Pri bolnikih, ki se jim je med zdravljenjem z zaviralci SGLT2 pojavila DKA, ponovna uvedba zdravljenja z zaviralci SGLT2 ni priporočljiva, razen če je ugotovljen in odpravljen kakšen drug nedvomen sprožilni dejavnik.
• carbamazepine, phenytoin, or phenobarbital (medicines used to control seizures) 
• karbamazepin, fenitoin ali fenobarbital (zdravila proti epileptičnim krčem)
• blood tests may show changes in blood fat (cholesterol) levels and increases in amount of red blood cells in your blood (haematocrit). 
• krvni testi lahko pokažejo spremembe koncentracij maščob (holesterola) in povečanje števila rdečih krvničk (hematokrita) v krvi
In other type 2 diabetes studies with canagliflozin, which enrolled a general diabetes population of approximately 5,800 patients, no difference in fracture risk was observed relative to control. 
V drugih študijah sladkorne bolezni tipa 2 s kanagliflozinom, v katere je bilo vključenih 5.800 bolnikov iz splošne populacije bolnikov s sladkorno boleznijo, razlik v tveganju za zlom kosti v primerjavi s kontrolno skupino niso opazili.
Significant improvements in body weight and reductions in systolic blood pressure compared to both glimepiride and sitagliptin were also observed. 
Poleg tega so opazili tudi pomembno zmanjšanje telesne mase in znižanje sistoličnega krvnega tlaka v primerjavi z glimepiridom in s sitagliptinom.
Insulin and insulin secretagogues, such as sulphonylureas, can cause hypoglycaemia. 
Insulin in spodbujevalci izločanja insulina, kot je sulfonilsečnina, lahko povzročijo hipoglikemijo.
This may affect your ability to drive, cycle, and use any tools or machines. 
To lahko vpliva tudi na sposobnost vožnje avtomobila ali kolesa ter uporabe naprav in strojev.
Subjects responded to standard treatments while continuing canagliflozin treatment. 
Bolniki so se odzvali na običajno zdravljenje in nadaljevali zdravljenje s kanagliflozinom.
• if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away. 
• če ste hitro izgubili telesno maso, vam je slabo ali bruhate, imate bolečine v trebuhu, ste hudo žejni, hitro in globoko dihate, ste zmedeni, neobičajno zaspani ali utrujeni, imate sladkast zadah, sladek ali kovinski okus v ustih ali spremenjen vonj urina ali znoja, takoj pokličite zdravnika ali pojdite v najbližjo bolnišnico.
Safety data profiles from individual pivotal studies (including studies in moderately renally impaired patients; older patients [≥ 55 years of age to ≤ 80 years of age]; patients with increased CV-risk) were generally consistent with the adverse reactions identified in this table. 
a Profili varnostnih podatkov iz posameznih ključnih študij (vključno s študijami z bolniki z zmerno okvaro ledvic, s starejšimi bolniki [starih od ≥ 50 do ≤ 80 let]; bolnikih s povečanim tveganjem za kardiovaskularne bolezni) so se večinoma ujemali z neželenimi učinki, ki so navedeni v tej preglednici.
Canagliflozin has not been studied in patients with severe hepatic impairment and is not recommended for use in these patients (see section 5.2). 
Kanagliflozina niso preučevali pri bolnikih s hudo okvaro jeter, zato uporabe pri teh bolnikih ne priporočamo (glejte poglavje 5.2).
4.4 Special warnings and precautions for use 
4.4 Posebna opozorila in previdnostni ukrepi Splošno
Canagliflozin is transported by P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). 
Kanagliflozin se prenaša vezan na P-glikoprotein (P-gp) in membranski transporterski protein (ABCG2 oz. BCRP - Breast Cancer Resistance Protein).
Limited data from clinical trials suggest that DKA occurs with common frequency when patients with type 1 diabetes are treated with SGLT2 inhibitors. 
Omejeni podatki kliničnih preskušanj kažejo, da se DKA pri bolnikih s sladkorno boleznijo tipa 1, ki so bili zdravljeni z zaviralci SGLT2, pojavi pogosto.
Enzyme inducers (such as St. John's wort [Hypericum perforatum], rifampicin, barbiturates, phenytoin, carbamazepine, ritonavir, efavirenz) may give rise to decreased exposure of canagliflozin. 
Induktorji encimov (kot so šentjanževka [Hypericum perforatum], rifampicin, barbiturati, fenitoin, karbamazepin, ritonavir in efavirenz) lahko povzročijo zmanjšano izpostavljenost kanagliflozinu.
In a pooled analysis of clinical data, increases in canagliflozin AUC of 26% were observed in UGT1A9*1/*3 carriers and 18% in UGT2B4*2/*2 carriers. 
Pri analizi združenih kliničnih podatkov so opazili povečanja v AUC kanagliflozina pri prenašalcih UGT1A9*1/*3 za 26% in pri prenašalcih UGT2B4*2/*2 za 18%.
In rare instances, phimosis was reported and sometimes circumcision was performed (see section 4.4). 
Poročali so o redkih primerih fimoze in v nekaj primerih so izvedli cirkumcizijo (glejte poglavje 4.4).
Invokana is available in PVC/aluminium perforated unit dose blisters. 
Zdravilo Invokana je na voljo v pretisnih omotih iz PVC/aluminija, perforiranih na posamezen odmerek.
Hypotension*, Orthostatic hypotension* 
Žilne bolezni občasni hipotenzija*, ortostatska hipotenzija*
When pregnancy is detected, treatment with canagliflozin should be discontinued. 
V primeru nosečnosti je treba zdravljenje s kanagliflozinom prekiniti.
In patients susceptible to greater reductions in intravascular volume as described above, larger decreases in eGFR (> 30%) were sometimes seen, which subsequently improved, and infrequently required interruption of treatment with canagliflozin (see section 4.8). 
Pri zgoraj navedenih bolnikih, ki so nagnjeni k bolj obsežnemu zmanjšanju znotrajžilnega volumna, so včasih opazili tudi bolj obsežno zmanjšanje ocenjene glomerulne filtracije (za > 30%), kar se je sčasoma popravilo, v redkih primerih je bila potrebna prekinitev zdravljenja s kanagliflozinom (glejte poglavje 4.8).
Canagliflozin is not recommended for use in patients receiving loop diuretics (see section 4.5) or who are volume depleted, e.g., due to acute illness (such as gastrointestinal illness). 
Uporaba kanagliflozina ni priporočena pri bolnikih, ki jemljejo diutetike Henleyeve zanke (glejte poglavje 4.5) ali pri bolnikih s hipovolemijo, npr. zaradi akutne bolezni (kot so gastrointestinalne bolezni).
Haematocrit increase was observed with canagliflozin treatment (see section 4.8); therefore, caution in patients with already elevated haematocrit is warranted. 
Pri zdravljenju s kanagliflozinom so opazili povečan hematokrit (glejte poglavje 4.8), zato pri bolnikih s predhodno povečanim hematokritom svetujemo previdnost.
Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level. 
Če se pojavijo ti simptomi, je treba takoj preveriti, ali gre za ketoacidozo, ne glede na koncentracijo glukoze v krvi.
Adverse reactions in table 1 are based on the pooled analysis of the four 26-week placebo-controlled studies (n=2,313) described above. 
Podatki o neželenih učinkih v preglednici 1 izhajajo iz zgoraj opisane analize združenih podatkov štirih 26-tedenskih, s placebom nadzorovanih študij (n = 2.313).